Circulating levels of soluble urokinase plasminogen activator receptor predict outcome after resection of biliary tract cancer.

ABSTRACT:

Background & aims

Surgical resection is the only potentially curative therapy for patients with biliary tract cancer (BTC), but 5-year survival rates after tumor resection have remained below 30%, corroborating the need for better stratification tools to identify the ideal surgical candidates. The soluble urokinase plasminogen activator receptor (suPAR) represents a mediator of inflammation and has been associated with distinct types of cancer. In this study, we evaluated a potential role of suPAR as a novel biomarker in patients undergoing BTC resection.

Methods

Tumor expression of uPAR was analyzed by immunohistochemistry in 108 BTC samples. Serum levels of suPAR were analyzed by ELISA in a training and validation cohort comprising a total of 117 patients with BTC and 76 h

SUBMITTER: Loosen SH 

PROVIDER: S-EPMC7049662 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature